Stockscreener 앱 받기
5.64
7.43%
0.39
전일 마감가:
$5.25
열려 있는:
$5.33
하루 거래량:
4.76M
Relative Volume:
1.02
시가총액:
$2.01B
수익:
$9.68M
순이익/손실:
$-250.64M
주가수익비율:
-4.0291
EPS:
-1.3998
순현금흐름:
$-89.83M
1주 성능:
+2.17%
1개월 성능:
+46.11%
6개월 성능:
+31.78%
1년 성능:
+250.31%
1일 변동 폭
$5.255
$5.66
1주일 범위
$5.20
$6.04
52주 변동 폭
$1.47
$6.04
Precigen Inc Stock (PGEN) Company Profile
명칭
Precigen Inc
전화
301-556-9900
주소
20374 SENECA MEADOWS PARKWAY, GERMANTOWN, MD
Compare PGEN vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PGEN
Precigen Inc
|
5.64 | 2.03B | 9.68M | -250.64M | -89.83M | -1.3998 |
VRTX
Vertex Pharmaceuticals Inc
|
528.04 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
654.27 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
939.68 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
312.78 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.24 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Precigen Inc Stock (PGEN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-15 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2024-03-22 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2023-05-23 | 개시 | JP Morgan | Neutral |
| 2022-11-18 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-02-25 | 개시 | Stifel | Buy |
| 2021-02-22 | 개시 | Wells Fargo | Overweight |
| 2021-02-18 | 개시 | B. Riley Securities | Buy |
| 2020-05-08 | 개시 | H.C. Wainwright | Buy |
모두보기
Precigen Inc 주식(PGEN)의 최신 뉴스
PGENPrecigen Inc Latest SEC Filings - Finviz
Insider Sell Alert: Harry Thomasian Sells 200,000 Shares of Prec - GuruFocus
Precigen CEO Helen Sabzevari sells $2.04m in PGEN stock - Investing.com
Precigen COO Rutul Shah sells $251,105 in company stock - Investing.com
Precigen (PGEN) COO sells 42,924 shares after option exercise - Stock Titan
Precigen CFO Harry Thomasian Jr. sells $1.1m in company stock - Investing.com Canada
[Form 4] PRECIGEN, INC. Insider Trading Activity - Stock Titan
Form 4 Precigen Inc For: 1 July By Investing.com - Investing.com Canada
Precigen COO Rutul Shah sells $251,105 in company stock By Investing.com - Investing.com Canada
Precigen (PGEN) CFO executes 200,000-share open-market sale under 10b5-1 plan - Stock Titan
Form 144 PRECIGEN For: 1 July By Investing.com - Investing.com Nigeria
PGEN (NASDAQ) affiliate files Rule 144 notice to sell 28,571 shares - Stock Titan
Does Precigen’s (PGEN) Russell Value Index Exit Signal a Shifting Investor Base or Story? - simplywall.st
[144] PRECIGEN, INC. SEC Filing - Stock Titan
Form 144 PRECIGEN For: 29 June By Investing.com - Investing.com South Africa
Precigen, Inc.(NasdaqGS: PGEN) dropped from Russell 2000 Value Benchmark - marketscreener.com
Precigen, Inc.(NasdaqGS: PGEN) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
Precigen, Inc.(NasdaqGS: PGEN) dropped from Russell 3000E Value Benchmark - marketscreener.com
Precigen: Entering The Oncology "Sweet Spot" (NASDAQ:PGEN) - Seeking Alpha
PGEN Forecast — Price Target — Prediction for 2027 - TradingView
Price to sales forward of Precigen, Inc. – NASDAQ:PGEN - TradingView
Precigen Inc Actuals & Estimates (BX:I5X) - TradingView
Precigen Shareholders Expand Incentive Plan, Reaffirm Governance - The Globe and Mail
Precigen (PGEN) investors back 7M-share incentive pool and all board picks - Stock Titan
Clearfield And 2 Insider Picks For Strong Growth - simplywall.st
Precigen (PGEN) Is Up 12.1% After Orphan Exclusivity Win for PAPZIMEOS TherapyWhat's Changed - Sahm
Precigen stock hits 52-week high at 5.47 USD By Investing.com - Investing.com Australia
Precigen stock hits 52-week high at 5.47 USD - Investing.com
Precigen Inc (PGEN) Institutional Confidence - TradingKey
Precigen (PGEN) Ends 11.6% Higher — This FDA Approval Could Hold the Reason - Insider Monkey
Precigen Gains FDA Orphan Drug Exclusivity for Gene Therapy Candidate PAPZIMEOSDebt Analysis Report - Město Břeclav
Precigen (PGEN) Secures FDA Orphan Drug Exclusivity for PAPZIMEOS - Insider Monkey
Precigen (PGEN) Stock Could Be 79% Undervalued After FDA Exclusivity Win - Sahm
PGEN News | PRECIGEN INC (NASDAQ:PGEN) - ChartMill
Precigen Inc (PGEN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
PGEN: All proposals, including board elections and compensation, passed overwhelmingly without shareholder questions - TradingView
PGEN: All proposals, including board elections and compensation, passed overwhelmingly without dissent - TradingView
Precigen Inc Annual Shareholders Meeting Transcript - GuruFocus
Precigen Inc (PGEN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Precigen Inc (PGEN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Precigen Inc (PGEN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Precigen Inc (PGEN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
5 Penny Stocks With Explosive Growth Potential - Insider Monkey
Precigen Inc (PGEN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Precigen Inc (PGEN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Precigen Inc (PGEN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
H.C. Wainwright Remains a Buy on Precigen (PGEN) - Insider Monkey
5 Best Penny Stocks That Could Skyrocket in 2026 - Insider Monkey
Precigen gains 7 year FDA orphan drug exclusivity - grafa.com
Precigen receives seven-year exclusivity for rare disease drug - Investing.com UK
Precigen receives seven-year exclusivity for rare disease drug By Investing.com - Investing.com India
Precigen Inc (PGEN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.86%
자본화:
|
볼륨(24시간):